Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 213-367-9 | CAS number: 939-97-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute Oral Toxicity, rat: LD50 = 50.6 mg/kg bw (BASF79/168)
Acute dermal toxicity, Rabbit: LD 50 > 2000 mg/kg bw (BASF79/168)
Key value for chemical safety assessment
Additional information
There are valid studies available for the assessment of the acute toxicity of t-butyl-benzaldehyde.
Oral:
In an acute oral toxicity study according to OECD TG 401 and GLP, five female Fü-albino SPF rats per dose group were treated with 200, 500 or 800 mg/kg bw (Givaudan 1990). One animal treated with 800 mg/kg bw died on the first test day. A depressed body weight development was observed in rats treated with 800 mg/kg bw. Clinical findings were diarrhea, soiled urogenital region and piloerection. No gross lesions were observed. The oral LD50 is > 800 mg/kg bw in this study.
In an acute oral toxicity study, i.e. a BASF test similar to OECD TG 401, five male and five female Sprague Dawley rats per group were treated with 14.7, 21.5, 31.6, 46.4 and 68.1 mg/kg bw under standardized conditions (BASF79/168). The animals were observed for 14 d, necropsy was performed even with the survivors. The LD50 was 50.6 mg/kg bw for male and female rats. None of the test animals died within the first 24 h after administration of the test material. Clinical signs of toxicity included dyspnoe, apathy, abnormal position, staggering, atony, narcotic, no pain and no corneal reflex, spastic movement, ruffled fur, diarrhea, cyanosis, exsiccosis, exophtalamus and a generally bad condition. At gross necropsy, acute dilatation on the right side and an acute congestion hyperemia was seen in the heart of the animals that died during the study; the liver was clay-like coloured due to slightly broadened Lobuli hepatici and the kidneys were brightened (nephrosis). No substance-related effects were seen in the sacrificed animals.
In two other acute oral toxicity studies using Charles River rats, beeing available als short summary from secondary sources, the LD50 values were determined to be >487 and <973 mg/kg bw or >800 and <1000 mg/kg bw after a 7 day observation period (TSCATS-OTS0510296; TSCATS-OTS0510298).
Overall, contradictive results are available for acute oral toxicity. However in a weight of evidence, the lowest LD50 determined will be used as the basis for the decision on classification of t-butyl-benzaldehyde.
Inhalation:
In a standardized inhalation hazard test 12 rats were exposed for 7 hours to an atmosphere that had been saturated at 20 °C with the volatile parts of the test compound (vapour) (BASF79/168). 0/12 rats died after 7 h exposure and no clinical signs were observed. At gross necropsy nothing abnormal was detected. The test concentration, i.e. 0.142 mg/l, has been determined by calculated of the substance weight loss and cumulative air flow during study (no analytical verification has been performed).
Dermal:
In the key study, i.e. an internal BASF test similar to OECD TG 402, p-tert-butylbenzaldehyde was administered dermally at doses of 200, 400, 1000 and 2000 mg/kg bw to 3 male and 3 female rats per dose group (BASF79/168). 1/6 animals of the 2000 mg/kg dose group died within the first two days. All other animals survived. Clinical signs of toxicity included dyspnea, apathy, aggressiveness, excitation, staggering, tremor, spastic movement, morphine tail, diarrhea and a generally bad condition. At gross necropsy, an acute dilatation on the right side as well as an acute congestion hyperemia of the heart was seen in the one animal that died during the study. Additionally, acute and moderate exhalation of the lung and brightened, clay-like coloured, broadened lobuli hepatici were seen in the liver. No substance-related effects were seen in all sacrificed animals. Reversible dermal irritation effects were observed.
Overall, the available data for p-tert-butylbenzaldehyde indicate a potential for acute toxicity, depending on the route of exposure.
Justification for classification or non-classification
The present data on acute oral toxicity do fulfill the criteria laid down in 67/548/EEC and 1272/2008/EEC, and therefore, a classification as "Toxic if swallowed" (R25 or Category 3) is warranted.
The present data on acute dermal toxicity do not fulfill the criteria laid down in 67/548/EEC and 1272/2008/EEC, and therefore, a non-classification is warranted. According to UN-GHS, the test substance needs to be classified as acute dermal toxicant (Category 5).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.